HomeBiotechnology

Biotechnology

Acadia (ACAD) Down More Than 30% in Past 3 Months: Here’s Why

Acadia (ACAD) Down More Than 30% in Past 3 Months: Here’s Why

July 8, 2022

Biohaven (BHVN) Begins Phase III Study on SMA Candidate

Biohaven (BHVN) Begins Phase III Study on SMA Candidate

July 8, 2022

Halozyme Therapeutics (HALO) Moves 7.3% Higher: Will This Strength Last?

Halozyme Therapeutics (HALO) Moves 7.3% Higher: Will This Strength Last?

July 8, 2022

SHAREHOLDER ALERT: AXSM IONQ NOTV: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

SHAREHOLDER ALERT: AXSM IONQ NOTV: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

July 7, 2022

Alkermes Announces Results of Annual General Meeting of Shareholders

Alkermes Announces Results of Annual General Meeting of Shareholders

July 7, 2022

LAWSUITS FILED AGAINST AXSM, SPRO and APYX – Jakubowitz Law Pursues Shareholders Claims

LAWSUITS FILED AGAINST AXSM, SPRO and APYX – Jakubowitz Law Pursues Shareholders Claims

July 7, 2022

Novavax (NVAX) Stock Rallies 26.8% in a Month: Here’s Why

Novavax (NVAX) Stock Rallies 26.8% in a Month: Here’s Why

July 7, 2022

Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies

Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies

July 7, 2022

The Zacks Analyst Blog Highlights ConocoPhillips SAP, CSX, Alnylam Pharmaceuticals and NVR

The Zacks Analyst Blog Highlights ConocoPhillips SAP, CSX, Alnylam Pharmaceuticals and NVR

July 7, 2022

Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)

Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)

July 7, 2022

« 1 … 23 24 25 26 27 … 543 »